Wuhan Yungu Biopharmaceutical Technology

Wuhan Yungu Biopharmaceutical Technology is a Chinese biotechnology company based in the Optics Valley of China (Wuhan National Bio-industry Base). The company focuses on the research and development of innovative cell therapies, particularly chimeric antigen receptor T-cell (CAR-T) therapies for the treatment and functional cure of HIV-1 infection and Acquired Immunodeficiency Syndrome (AIDS). Its proprietary technology involves constructing multi-functional and dual-targeting CAR-T cells that target HIV envelope proteins such as gp120 and gp41, as well as host cell receptors like CD4, to effectively eliminate active and latent HIV-1 reservoirs. Wuhan Yungu Biopharmaceutical Technology's pipeline is currently in the pre-clinical stage, supported by robust in vitro and in vivo proof-of-concept data.